Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis

JHEP Reports : Innovation in Hepatology
Pinelopi ArvanitiGeorge N Dalekos

Abstract

Autoimmune hepatitis (AIH) is a disease of unknown aetiology with a favourable response to immunosuppression. However, in the clinic, it appears that <50% of patients achieve complete response on standard treatment. Serum B cell-activating factor (BAFF) levels are elevated in patients with AIH and are likely to contribute to disease pathogenesis. Given that belimumab, a BAFF inhibitor, has been shown to be effective in other autoimmune diseases, we investigated its use as a third-line add-on treatment option in patients with advanced AIH who did not respond to conventional treatment. Herein, we report for the first time two patients, a 27-year-old female and a 58-year-old male, both with AIH-related compensated cirrhosis at diagnosis, who were refractory to standard immunosuppressive therapies and received add-on third-line therapy with belimumab. Both patients achieved a complete response and remained in remission while receiving low-dose corticosteroids. No adverse events related to belimumab and/or disease decompensation were observed. These preliminary findings indicate belimumab as a promising treatment option for patients with AIH and refractory and advanced liver-related fibrosis. A small proportion of patients with auto...Continue Reading

Citations

Dec 15, 2020·Current Opinion in Gastroenterology·Christina Weiler-Normann, Ansgar W Lohse
Oct 29, 2020·Cellular & Molecular Immunology·Andrea Kristina HorstGisa Tiegs
May 4, 2021·Frontiers in Immunology·Tamsin Cargill, Emma L Culver
Sep 11, 2021·Alimentary Pharmacology & Therapeutics·Albert J Czaja

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
biopsy
SMA

Clinical Trials Mentioned

NCT03217422

Related Concepts

Related Feeds

Autoimmune Hepatitis

Autoimmune hepatitis formerly called lupoid hepatitis, is a chronic, autoimmune disease of the liver that occurs when the body's immune system attacks liver cells causing the liver to be inflamed. Discover the latest research on autoimmune hepatitis here.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.